Immunocore Holdings jumps on FDA approval of cancer drug

Immunocore Holdings

26/01/2022 14:15

** U.S.-listed shares of Britain-based drug developer
 IMCR.O  up 12.7% at $24.72 premarket 
    ** Co says U.S. FDA approved its lead drug candidate for
treating a type of cancer that affects the eye  urn:newsml:reuters.com:*:nBw6RDX3ca
    ** FDA action represents first U.S. approval for a drug to
treat patients with uveal melanoma that has spread to other
parts of the body, or cannot be surgically removed 
    ** Stock is down ~15% from IPO price of $26

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))